Insulin Aspart
Cystic Fibrosis-related Diabetes
University Hospital, Strasbourg, FrancePhase 4 / ApprovedDormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 89/ 100
Competitive context
7 Active assets in the Cystic Fibrosis-related Diabetes cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Humulin R University of Cambridge | Phase 4 | BB |
Novo Rapid Insulin University Hospital, Strasbourg, France | Phase 4 | B |
Semaglutide University of Minnesota | Phase 2/3 | B |
Empagliflozin University of Minnesota | Phase 2/3 | B |
Capecitabine University of Minnesota | Phase 2/3 | B |
Metformin University of Kansas Medical Center | Phase 2 | CCC |
GLUCOSE, ANHYDROUS Children's Hospital of Philadelphia | Early Phase 1 | CCC |
Dorzagliatin University of Pennsylvania | Phase 1 | CC |
Same molecule, other indications
Insulin Aspart is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →